Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab

Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab

Introduction: Enfortumab vedotin (EV) combined with pembrolizumab (EV+P) is a promising first-line therapy for metastatic urothelial carcinoma. While it has shown significant efficacy, severe cutaneous adverse events such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have be...

Full description

Saved in:
Bibliographic Details
Main Authors: Benjamin Müller, Riccardo Curatolo, Hazem Juratli, Almir Husic, Josephine Nehring, Eliska Potlukova, Angela Kohler
Format: Article
Language:English
Published: SMC MEDIA SRL 2024-11-01
Series:European Journal of Case Reports in Internal Medicine
Subjects:
enfortumab vedotin
pembrolizumab
stevens-johnson syndrome (sjs)
toxic epidermal necrolysis (ten)
cutaneous toxicity
Online Access:https://www.ejcrim.com/index.php/EJCRIM/article/view/5003
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ejcrim.com/index.php/EJCRIM/article/view/5003

Similar Items